Resources Repository
-
ReviewPublication 2001Modeling for Health Care and Other Policy Decisions: Uses, Roles and Validity
This is a review article of the role of modeling approaches to guide decision making …
This is a review article of the role of modeling approaches to guide decision making in health care and other domains. The role of models to support recommendations on the cost-effective use of medical technologies and pharmaceuticals is controversial. At the heart of the controversy is the degree to which experimental or other empirical evidence should be required prior to model use. The authors argue that the controversy stems in part from a misconception that…
Priority Setting/Ethics | Technology Assessment | Health/Medicine | Climate/Environment | Policy/Regulation | Evidence Synthesis | Mathematical Models | Environmental Health | Health Systems | Business/Industry | Economics/Finance | Energy/Engineering | Government/Law | North America -
ArticlePublication 2021Correct COVID-19 Vaccine Misinformation: Lancet Commission on COVID-19 Vaccines & Therapeutics Task Force Members
This brief “primer” assists healthcare providers in correcting a growing body of misinformation surrounding COVID-19 …
This brief “primer” assists healthcare providers in correcting a growing body of misinformation surrounding COVID-19 vaccines. In 2020, up to one-third or more of people surveyed both globally and in the U.S. indicated they might refuse the first COVID-19 vaccines when released through emergency use authorization (EUA). Their rationale included questions about vaccine efficacy, potential side effects, or speeding through regulatory approval processes. Even among healthcare workers, high rates of COVID-19 vaccine hesitancy were noted.…
Preferences/Values | Health/Medicine | Global Governance | Policy/Regulation | Social Determinants | Infectious Diseases | Culture/Society | Science/Technology | Global -
Resource PackWeb Portal, Teaching Resource 2017Resource Pack: Valuing Vaccines and GAVI
This resource pack on valuing vaccines and GAVI was curated by the Center for Health …
This resource pack on valuing vaccines and GAVI was curated by the Center for Health Decision Science to showcase existing information and analyses to motivate students, educators and others to pursue new applications of decision science methods to the public health challenge of vaccine preventable illnesses.
Priority Setting/Ethics | Preferences/Values | Calibration/Validation | Health/Medicine | Global Governance | Costing Methods | Mathematical Models | Dynamic Transmission | Benefit-Cost Analysis | Cost-Effectiveness Analysis | Infectious Diseases | Child/Nutrition | Health Systems | Economics/Finance | Government/Law | Science/Technology | Global | Graduate | Doctoral | Professional | Critical Thinking/Analysis | Policy Translation | Quantitative Literacy -
BookPublication 2016Cost-Effectiveness in Health and Medicine, 2nd Edition
This is a revised and expanded edition of the original text on Cost-Effectiveness in Health and Medicine. The …
This is a revised and expanded edition of the original text on Cost-Effectiveness in Health and Medicine. The Second Panel on Cost-Effectiveness in Health and Medicine included experts drawn from academia, healthcare administration, and government. The book offers advice for conducting analyses to improve the allocation of health resources, and is intended for economists, policy analysts, hospital executives, and students across health, business, and humanities disciplines. New components of this edition, include an in-depth review of the past 20…
Priority Setting/Ethics | Preferences/Values | Technology Assessment | Health/Medicine | Policy/Regulation | Costing Methods | Health Outcomes | Mathematical Models | Cost-Effectiveness Analysis | Health Systems | Economics/Finance | Global | North America | Europe -
ArticlePublication 2016“Nudges” in Law and Policy
This article describes research on Americans’ preferences for types of “nudges” in the context of …
This article describes research on Americans’ preferences for types of “nudges” in the context of law and public policy—those that target “system 1” thinking, meaning the intuitive, emotion-based mechanisms, such as graphic warnings and default rules, versus those that target “system 2” thinking, the rational, deliberative form of cognition, such as statistical information or education-based messages.
Priority Setting/Ethics | Preferences/Values | Decision Psychology | Health/Medicine | Policy/Regulation | Culture/Society | Government/Law -
BookPublication 2013Making Hard Decisions with Decision Tools, 3rd Edition
Making Hard Decisions with Decision Tools® is a new edition and teaches the fundamental ideas …
Making Hard Decisions with Decision Tools® is a new edition and teaches the fundamental ideas of decision analysis, without an overly technical explanation of the mathematics used in decision analysis. This new version has been purposefully written to be more relevant to students in business and engineering compared to previous versions. This new version also incorporates and implements the powerful DecisionTools® software by Palisade Corporation. At the end of each chapter, topics are illustrated with step-by-step instructions…
Preferences/Values | Probability/Bayes | Value of Information | Health/Medicine | Policy/Regulation | Test Performance | Microsimulation | Decision Analysis | Business/Industry | Energy/Engineering | Military/Defense | Science/Technology | Global | North America | Europe -
BookPublication 1996Cost-Effectiveness in Health and Medicine, 1st Edition
In 1993, the US Public Health Service convened a panel of 13 nongovernment scientists and …
In 1993, the US Public Health Service convened a panel of 13 nongovernment scientists and scholars with expertise in economics, clinical medicine, ethics, and statistics to review the state of cost-effectiveness analysis and to develop recommendations for its conduct and use in health and medicine. Publishing their results in 1996, they proposed the most explicit set of guidelines (together with their rationale) ever defined on the conduct of CEAs. The panel recommended analysts include a "reference-case"…
Priority Setting/Ethics | Preferences/Values | Value of Information | Health/Medicine | Policy/Regulation | Costing Methods | Health Outcomes | Evidence Synthesis | Cost-Effectiveness Analysis | Health Systems | Economics/Finance | North America -
Resource PackPublication, Teaching Resource 2024Resource Pack: Extended Cost-Effectiveness Analysis
Health policies are intended to increase the uptake of effective and efficient interventions and result …
Health policies are intended to increase the uptake of effective and efficient interventions and result in health gains (e.g., premature mortality and morbidity averted). Health policies can also provide non-health benefits in addition to the sole well-being of populations and beyond the health sector. For instance, social and health insurance programs can prevent illness-related impoverishment and provide financial risk protection. Health policies can also improve the distribution of health in the population and promote health…
Priority Setting/Ethics | Health/Medicine | Policy/Regulation | Social Determinants | Costing Methods | Cost-Effectiveness Analysis | Health Systems | Culture/Society | Economics/Finance | Global | Graduate | Doctoral | Professional | Critical Thinking/Analysis | Decision Making/Leadership | Quantitative Literacy -
ReviewPublication 2023Systematic Literature Review of Gaps and Challenges in Value Assessment of Biosimilars: ISPOR Special Interest Group Report
This study addresses the gaps and challenges in the value assessment of biosimilars and proposes …
This study addresses the gaps and challenges in the value assessment of biosimilars and proposes potential approaches to mitigate them. A multidisciplinary team of biosimilar experts conducted a systematic review of literature and engaged in review rounds to identify these challenges. The article suggests that health technology assessment agencies should accept the comparability exercise approved by regulatory authorities and conduct price comparisons for biosimilars reimbursed for the same indication as the reference biologic. In cases…
Preferences/Values | Technology Assessment | Health/Medicine | Policy/Regulation | Evidence Synthesis